S&P 500   3,114.99 (+0.07%)
DOW   27,665.24 (+0.06%)
QQQ   202.62 (+0.09%)
AAPL   265.23 (+1.33%)
FB   199.05 (+0.17%)
MSFT   150.00 (+0.10%)
GOOGL   1,325.10 (+0.47%)
AMZN   1,748.82 (-0.67%)
NVDA   208.75 (-0.32%)
MU   46.43 (+0.26%)
BABA   199.87 (+3.16%)
TSLA   331.47 (-0.47%)
T   38.32 (+0.55%)
AMD   39.73 (+0.10%)
ACB   2.44 (-1.61%)
F   8.91 (-0.45%)
NFLX   300.68 (-1.20%)
BAC   33.12 (-0.09%)
S&P 500   3,114.99 (+0.07%)
DOW   27,665.24 (+0.06%)
QQQ   202.62 (+0.09%)
AAPL   265.23 (+1.33%)
FB   199.05 (+0.17%)
MSFT   150.00 (+0.10%)
GOOGL   1,325.10 (+0.47%)
AMZN   1,748.82 (-0.67%)
NVDA   208.75 (-0.32%)
MU   46.43 (+0.26%)
BABA   199.87 (+3.16%)
TSLA   331.47 (-0.47%)
T   38.32 (+0.55%)
AMD   39.73 (+0.10%)
ACB   2.44 (-1.61%)
F   8.91 (-0.45%)
NFLX   300.68 (-1.20%)
BAC   33.12 (-0.09%)
S&P 500   3,114.99 (+0.07%)
DOW   27,665.24 (+0.06%)
QQQ   202.62 (+0.09%)
AAPL   265.23 (+1.33%)
FB   199.05 (+0.17%)
MSFT   150.00 (+0.10%)
GOOGL   1,325.10 (+0.47%)
AMZN   1,748.82 (-0.67%)
NVDA   208.75 (-0.32%)
MU   46.43 (+0.26%)
BABA   199.87 (+3.16%)
TSLA   331.47 (-0.47%)
T   38.32 (+0.55%)
AMD   39.73 (+0.10%)
ACB   2.44 (-1.61%)
F   8.91 (-0.45%)
NFLX   300.68 (-1.20%)
BAC   33.12 (-0.09%)
S&P 500   3,114.99 (+0.07%)
DOW   27,665.24 (+0.06%)
QQQ   202.62 (+0.09%)
AAPL   265.23 (+1.33%)
FB   199.05 (+0.17%)
MSFT   150.00 (+0.10%)
GOOGL   1,325.10 (+0.47%)
AMZN   1,748.82 (-0.67%)
NVDA   208.75 (-0.32%)
MU   46.43 (+0.26%)
BABA   199.87 (+3.16%)
TSLA   331.47 (-0.47%)
T   38.32 (+0.55%)
AMD   39.73 (+0.10%)
ACB   2.44 (-1.61%)
F   8.91 (-0.45%)
NFLX   300.68 (-1.20%)
BAC   33.12 (-0.09%)
Log in

TSE:GUD - Knight Therapeutics Stock Price, Forecast & News

C$7.70
+0.09 (+1.18 %)
(As of 12/5/2019 02:11 PM ET)
Today's Range
C$7.60
Now: C$7.70
C$7.75
50-Day Range
C$7.50
MA: C$7.97
C$8.76
52-Week Range
C$7.10
Now: C$7.70
C$8.88
Volume129,158 shs
Average Volume305,518 shs
Market CapitalizationC$1.04 billion
P/E Ratio50.99
Dividend YieldN/A
BetaN/A
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. Read More…

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone514-484-4483

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$14.08 million
Cash FlowC$4.27 per share
Book ValueC$7.06 per share

Profitability

Miscellaneous

Employees27
Market CapC$1.04 billion
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive GUD News and Ratings via Email

Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.


Knight Therapeutics (TSE:GUD) Frequently Asked Questions

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD."

When is Knight Therapeutics' next earnings date?

Knight Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Knight Therapeutics.

What price target have analysts set for GUD?

4 brokerages have issued 1-year price objectives for Knight Therapeutics' shares. Their forecasts range from C$8.50 to C$10.25. On average, they expect Knight Therapeutics' share price to reach C$9.58 in the next twelve months. This suggests a possible upside of 24.5% from the stock's current price. View Analyst Price Targets for Knight Therapeutics.

What is the consensus analysts' recommendation for Knight Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics.

Has Knight Therapeutics been receiving favorable news coverage?

Media coverage about GUD stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Knight Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Knight Therapeutics.

Who are some of Knight Therapeutics' key competitors?

What other stocks do shareholders of Knight Therapeutics own?

Who are Knight Therapeutics' key executives?

Knight Therapeutics' management team includes the folowing people:
  • Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)
  • Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)
  • Mr. Michel Loustric, Pres of Knight Barbados
  • Ms. Amal Khouri, VP of Bus. Devel.
  • Ms. Jody Engel, Director of Bus. Devel.

How do I buy shares of Knight Therapeutics?

Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Knight Therapeutics' stock price today?

One share of GUD stock can currently be purchased for approximately C$7.70.

How big of a company is Knight Therapeutics?

Knight Therapeutics has a market capitalization of C$1.04 billion and generates C$14.08 million in revenue each year. Knight Therapeutics employs 27 workers across the globe.View Additional Information About Knight Therapeutics.

What is Knight Therapeutics' official website?

The official website for Knight Therapeutics is http://www.gud-knight.com/.

How can I contact Knight Therapeutics?

The company can be reached via phone at 514-484-4483.


MarketBeat Community Rating for Knight Therapeutics (TSE GUD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  118
MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/5/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel